reports
New Analysis of Pombiliti® (cipaglucosidase alfa-atga) + Opfolda® (mig...
New Analysis of Pombiliti® (cipaglucosidase alfa-atga) + Opfolda® (miglustat) Published in Muscle and Nerve PRINCETON, N.J., June 03, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: FOLD), today announced the publication of a post-hoc analysis of data from the ERT-experienced cohort of the PROPEL study of cipaglucosidase alfa-atga + miglustat (cipa+mig) in adults with late-onset Pompe disease (LOPD) in . In this new publication, based on a within group effect-size analysis, subjects who switched from alglucosidase alfa to cipa+mig achieved improvements or stability in most of the outcomes measured. ...
Amicus Therapeutics to Present at Upcoming Investor Conferences in Jun...
Amicus Therapeutics to Present at Upcoming Investor Conferences in June 2025 PRINCETON, N.J., May 30, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in upcoming presentations at the following investor conferences in June. Jefferies Global Healthcare Conference 2025 in New York, NY, on Wednesday, June 4, 2025, at 11:40 a.m. ETGoldman Sachs 46th Annual Global Healthcare Conference 2025 in Miami, FL, on Tuesday, June 10, 2025, at 2:00 p.m. ET A live audio webcast of each presentation can also be accessed via the investors sectio...
Carpenter Technology Corp: 1 director
A director at Carpenter Technology Corp sold 5,000 shares at 235.033USD and the significance rating of the trade was 69/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two yea...
Amicus Therapeutics to Present at the Bank of America 2025 Health Care...
Amicus Therapeutics to Present at the Bank of America 2025 Health Care Conference PRINCETON, N.J., May 07, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in a fireside chat at the Bank of America 2025 Health Care Conference in Las Vegas, NV on Wednesday, May 14, 2025, at 8:00 a.m. P.T. A live audio webcast of the presentation can also be accessed via the investors section of the Amicus Therapeutics corporate website at . About Amicus Therapeutics Amicus Therapeutics (Nasdaq: FOLD) is a global, patient-dedicated biotechnology ...
Amicus Therapeutics Announces First Quarter 2025 Financial Results and...
Amicus Therapeutics Announces First Quarter 2025 Financial Results and Corporate Updates 1Q 2025 Total Revenue of $125.2M, a 15% Increase Year-over-Year at CER Expanding Portfolio through In-Licensing of DMX-200 Phase 3 Program for Rare Kidney Disease with Significant Market Potential in the U.S. Maintaining 2025 Guidance for Galafold, Reflecting Strong Underlying Demand Updating 2025 Pombiliti + Opfolda Guidance with New Patient Starts Accelerating in 2H Adjusting 2025 Total Revenue Growth Guidance to 15-22% at CER Reiterating GAAP Profitability During H2 2025 Conference Call and We...
Dimerix and Amicus Therapeutics Announce Exclusive License Agreement f...
Dimerix and Amicus Therapeutics Announce Exclusive License Agreement for DMX-200 in the United States Amicus licenses exclusive U.S. rights to commercialize DMX-200 for the treatmentof Focal Segmental Glomerulosclerosis (FSGS) DMX-200 is in a pivotal Phase 3 trial for FSGS, a rare and fatal kidney disease with no FDA-approved therapies Dimerix successfully completed Type C meeting with the FDA in March 2025, aligning on proteinuria as the primary endpoint for approval Dimerix to receive US$30 million (~AU$48 million) upfront payment, up to US$560 million (~AU$892 million) for success-ba...
Carpenter Technology Reports Third Quarter Fiscal Year 2025 Results
Carpenter Technology Reports Third Quarter Fiscal Year 2025 Results Delivered Most Profitable Quarter in Company HistoryExceeded Third Quarter Operating Income GuidanceExpanded Operating Margins in Specialty Alloys Operations SegmentGenerated Positive Adjusted Free Cash FlowRepurchased Shares Against Authorized Share Repurchase ProgramRaising Fiscal Year 2025 Guidance PHILADELPHIA, April 24, 2025 (GLOBE NEWSWIRE) -- Carpenter Technology Corporation (NYSE: CRS) (the “Company”) today announced financial results for the fiscal third quarter ended March 31, 2025. For the quarter, ...
Amicus Therapeutics to Announce First Quarter 2025 Financial Results o...
Amicus Therapeutics to Announce First Quarter 2025 Financial Results on May 1, 2025 PRINCETON, N.J., April 21, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Thursday, May 1, 2025, at 8:30 a.m. ET to discuss financial results for the first quarter ended March 31, 2025. Participants and investors interested in accessing the call by phone will need to register using the . After registering, all phone participants will receive a dial-in number along with a personal PIN to access the event. A ...
Carpenter Technology Declares Quarterly Cash Dividend
Carpenter Technology Declares Quarterly Cash Dividend PHILADELPHIA, April 10, 2025 (GLOBE NEWSWIRE) -- Carpenter Technology Corporation (NYSE: CRS) announced that its Board of Directors has declared a quarterly cash dividend of $0.20 per share of common stock, payable June 5, 2025, to shareholders of record on April 22, 2025. About Carpenter Technology Carpenter Technology Corporation is a recognized leader in high-performance specialty alloy materials and process solutions for critical applications in the aerospace and defense, medical, and other markets. Founded in 1889, Carpenter Tec...
Carpenter Technology Announces Conference Call and Webcast
Carpenter Technology Announces Conference Call and Webcast PHILADELPHIA, April 04, 2025 (GLOBE NEWSWIRE) -- Carpenter Technology Corporation (NYSE: CRS) plans to host a conference call and webcast on Thursday, April 24, 2025 at 10:00 a.m. ET to discuss the results of operations for the third quarter of fiscal year 2025, ended March 31, 2025. The call and webcast will follow the release of third quarter fiscal 2025 financial results before the market opens on Thursday, April 24, 2025. Conference Call and Webcast Details What: Carpenter Technology Third Quarter Fiscal 2025 Conference Cal...
Kingsway Financial Services Inc: 1 director
A director at Kingsway Financial Services Inc sold 1,000,000 shares at 8.000USD and the significance rating of the trade was 72/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last...
- MarketLine Department
Gloria Material Technology Corporation - Company Profile and SWOT Anal...
Summary Gloria Material Technology Corporation - Company Profile and SWOT Analysis, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company. Key Highlights Gloria Material Technology Corp (GMTC), is a manufacturer of special steel material. It manufactures and distributes special alloy materials such as super alloy, high speed steel,...
Amicus Therapeutics to Present at Upcoming Investor Conferences in Mar...
Amicus Therapeutics to Present at Upcoming Investor Conferences in March 2025 PRINCETON, N.J., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in upcoming presentations at the following investor conferences in March. TD Cowen 45th Annual Health Care Conference in Boston, MA, on Tuesday, March 4, 2025, at 9:50 a.m. ETLeerink Partners 2025 Global Healthcare Conference in Miami, FL, on Monday, March 10, 2025, at 10:00 a.m. ET A live audio webcast of each presentation can also be accessed via the investors section of the ...
Farmers National Banc Corp. Declares Quarterly Cash Dividend
CANFIELD, Ohio--(BUSINESS WIRE)-- On February 25, 2025, the Board of Directors of the Farmers National Banc Corp. (NASDAQ: FMNB) declared a quarterly cash dividend of $0.17 per share. The common stock cash dividend will have a record date of March 14, 2025, and is payable to shareholders on March 31, 2025. ABOUT FARMERS NATIONAL BANC CORP. Founded in 1887, Farmers National Banc Corp. is a diversified financial services company headquartered in Canfield, Ohio, with $5.1 billion in banking assets. Farmers National Banc Corp.’s wholly-owned subsidiaries are comprised of The Farmers National B...
Julie A. Beck Joins Carpenter Technology’s Board of Directors
Julie A. Beck Joins Carpenter Technology’s Board of Directors PHILADELPHIA, Feb. 21, 2025 (GLOBE NEWSWIRE) -- Carpenter Technology Corporation (NYSE: CRS) announced today that Julie A. Beck has been appointed to the Company’s Board of Directors, effective February 20, 2025. The Board of Directors now consists of 12 members, 11 of whom are independent directors. Ms. Beck brings extensive experience in leading finance organizations at major manufacturing companies over the last three decades. Ms. Beck was most recently the Senior Vice President, Chief Financial Officer for Terex Corporatio...
Amicus Therapeutics Announces Full-Year 2024 Financial Results and Cor...
Amicus Therapeutics Announces Full-Year 2024 Financial Results and Corporate Updates 2024 Total Revenue of $528.3M, a 33% Increase Year-over-Year Projecting 2025 Total Revenue Growth of 17-24% at CER Anticipate Achieving Positive GAAP Net Income During H2 2025 Conference Call and Webcast Today at 8:30 a.m. ET PRINCETON, N.J., Feb. 19, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for rare diseases, today announced financial results for the full-year ended December 31, 2024. “We clo...
Amicus Therapeutics to Announce Full-Year 2024 Financial Results on Fe...
Amicus Therapeutics to Announce Full-Year 2024 Financial Results on February 19, 2025 PRINCETON, N.J., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Wednesday, February 19, 2025, at 8:30 a.m. ET to discuss financial results for the full-year ended December 31, 2024. Participants and investors interested in accessing the call by phone will need to register using the . After registering, all phone participants will receive a dial-in number along with a personal PIN to access the ...
Amicus Therapeutics Announces Presentations and Posters at the 21st An...
Amicus Therapeutics Announces Presentations and Posters at the 21st Annual WORLDSymposium™ 2025 PRINCETON, N.J., Feb. 03, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: FOLD), today announced that two oral presentations and 20 posters across its development programs will be included at the , being held February 3-7, 2025 in San Diego, CA. “As part of our ongoing efforts to advance our scientific leadership in Fabry and Pompe diseases, Amicus researchers will present two oral presentations and 20 posters at this year’s WORLDSymposium,” said Bradley Campbell, President and Chief Executive Officer of A...
Carpenter Technology Reports Second Quarter Fiscal Year 2025 Results
Carpenter Technology Reports Second Quarter Fiscal Year 2025 Results Delivered Record Second Quarter Operating IncomeExpanded Operating Margins in Specialty Alloys Operations SegmentGenerated Positive Adjusted Free Cash FlowRepurchased Shares Against Authorized Share Repurchase ProgramIncreased FY25 OutlookInvestor Event Scheduled PHILADELPHIA, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Carpenter Technology Corporation (NYSE: CRS) (the “Company”) today announced financial results for the fiscal second quarter ended December 31, 2024. For the quarter, the Company reported operating income of $...
Farmers National Banc Corp. Reports Solid Earnings and Improving Margi...
CANFIELD, Ohio--(BUSINESS WIRE)-- Farmers National Banc Corp. (“Farmers” or the “Company”) (NASDAQ: FMNB) today reported net income of $14.4 million, or $0.38 per diluted share, for the quarter ended December 31, 2024, compared to $14.6 million, or $0.39 per diluted share, for the quarter ended December 31, 2023. Net income for the fourth quarter of 2024 included certain pretax items. Excluding these items (non-GAAP), net income for the fourth quarter of 2024 was $14.5 million, or $0.39 per diluted share. Kevin J. Helmick, President and CEO, stated “Our team has done an outstanding job navig...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.